Lol like Dndn do more homework. DNDN needed pts own cells then had to infuse back into pts at a cost of 70k for 1st treatment no insurance would ever cover it.
Afrezza is the perfect prandial insulin lowering A1C values to the 5s unheard of with humalog and novolog, data will show this at ADA in June.
As for sny they made an offer to buy out Mnkd in the fall for only 2b and Al Mann of course would not even negotiate. Sny never launched the drug period you should know this being as educated as you are. There whole plan was to buy them out after crushing them wth Goldman Sachs.
Did you know sny priced all doses of Afrezza at 410 dollars???? Why would they do this when equal units of humalog sells for 180 dollars????
Afrezza will be priced at 210 estimate in May and be the insulin of choice in diabetes treatment centers of America in June.
If you need to refer back to a similar story look at the manipulation of AVNR prior being bought out. This should go down the same but at least five times the buyout price. Nudexta is a joke but was bought out for 2b. Watch the institutional ownership of Mnkd on next reporting it will be double and Goldman will now own north of 20m shares Susquehanna will now hold north of 30m SSB north of 15m. I like you ex get some shares easy ten times your money by years end.
Market Data 
Markets 
AI
